Rg1 treatment elevated center time to 124.2 ± 15.11 s (5 mg/kg, p = 0.107 vs. VPA) and 134.9 ± 15.37 s (10 mg/kg, p = 0.011 vs. VPA), with the latter dose significantly alleviating VPA‐induced anxiety‐like behavior (p = 0.521 between Rg1 groups). Here, PPP1R3A is linked to Anxiety.